27 July 2020 - ) -- Lumos Pharma today announced that it has entered into a definitive agreement to sell its Priority Review Voucher to Merck, known as MSD outside the United States and Canada.

The priority review voucher was granted in conjunction with the approval by the U.S. FDA of Ervebo, a vaccine developed by the Company’s licensee, Merck, for the prevention of the Zaire Ebola virus disease. Under the terms of the original license agreement Lumos Pharma is entitled to retain 60% of the value of the voucher. 

Based upon an agreed valuation of $100 million Merck will pay Lumos Pharma $60 million. The transaction remains subject to customary closing conditions, including anti-trust review.

Read Lumos Pharma press release